CAR T-cell therapy for cancer

The American Society of Clinical Oncology publishes a Clinical Cancer Advances report annually. CAR T-cell therapy was presented as one of the main achievements of the year in the report for 2018. This therapy was a breakthrough in oncology, mainly in the treatment of hematologic diseases. Today, some countries use CAR T immunotherapy not only in clinical trials, but also in practical medicine.

The chimeric antigen receptor (CAR) is a recombinant receptor, which enables a CD-8 T-lymphocyte (immune cell) to activate and interact with a tumor cell.

If CAR destroуed all cells in our body, the treatment would not be possible. These receptors work on the principle of a "homing missile". They are injected into the body, where they independently find and destroy malignant foci. At the same time, CAR T immunotherapy does not harm healthy tissues.

The targets for CAR are antigens that are absent in healthy cells. These antigens are only present on the surface of cancer cells. Therefore, CAR therapy is well tolerated by most patients. You should not be afraid that excessively active immunity will destroy your body.

Most often, CAR is used in the treatment of lymphomas, leukemia, and myeloma. The greatest progress has been made in this particular medical field.

If you need information about the best specialized hospitals and prices for CAR T-cell immunotherapy, you can easily find it on the Booking Health website.

?? To learn more about CAR T-cell therapy for cancer, check out our new blog article: https://bit.ly/4gbASl2

?? To get professional help in planning treatment abroad, leave an enquiry on our website: https://bit.ly/3HlssY5

#BookingHealth #immunotherapy #cancer #CART #treatmentabroad #treatmentabroad #treatmentingermany #medicaltourism